Possibia

5300438

Last Update Posted: 2024-06-25

Recruiting has ended

All Genders

accepted

18 Years +

74 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies.

Eligibility

Relevant conditions:

Cancer (With or Without Metastasis)

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

Cindy Li

li_jing_cindy@tyligand.com

+86-021-50720081

Data sourced from ClinicalTrials.gov